We are live on !
Find out more
Clarius Group LLC Portfolio holdings
AUM
$1.75B
Turnover
9.73%
1-Year Est. Return
19.04%
Clarius Group is a multi-family office that serves ultra-high-net-worth individuals and families. It provides investment advice, family office services and personal accounting. Keith Vernon and Matthew Talbot are among its founding partners. Clearstead Advisors, an investment adviser, bought the firm in a deal that closed in January 2026.
This Fund
S&P 500
This Quarter Est. Return
+3.84%
1 Year Est. Return
+19.04%
3 Year Est. Return
+92.07%
5 Year Est. Return
+98.79%
10 Year Est. Return
+415.93%
AUM
$1.75B
AUM Growth
+$62.2M
(+3.7%)
Cap. Flow
+$9.49M
Cap. Flow % of AUM
Cap. Flow %
0.54%
Top 10 Holdings %
Top 10 Hldgs %
59.64%
Holding
411
New
13
Increased
98
Reduced
159
Closed
27
Avg Time Held
4.7
years
Top 10 Avg Time Held
5
years
Top 20 Avg Time Held
4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Capital Group Global Equity ETF
CGGE
|
+$34.5M |
| 2 |
Vanguard Ultra-Short Bond ETF
VUSB
|
+$5.25M |
| 3 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$1.33M |
| 4 |
Dimensional International High Profitability ETF
DIHP
|
+$1.2M |
| 5 |
iShares Core MSCI International Developed Markets ETF
IDEV
|
+$974K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$4.12M |
| 2 |
Invesco Russell 1000 Dynamic Multifactor ETF
OMFL
|
+$3.17M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$1.85M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.69M |
| 5 |
Invesco Short Term Treasury ETF
TBLL
|
+$1.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.23% |
| 2 | Industrials | 16.65% |
| 3 | Technology | 15.34% |
| 4 | Consumer Discretionary | 6.93% |
| 5 | Financials | 3.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
Boston Scientific
BSX
$61.5B
| $762K | 0.04% |
7,987
-2
| -0% | -$196 |
2019 Q1
27 quarters
|
|
152
Invesco NASDAQ Next Gen 100 ETF
QQQJ
$1.19B
| $759K | 0.04% |
20,601
| – | – |
2022 Q2
14 quarters
|
|
153
Philip Morris
PM
$316B
| $741K | 0.04% |
4,618
-1,450
| -24% | -$225K |
2019 Q1
27 quarters
|
|
154
Automatic Data Processing
ADP
$113B
| $738K | 0.04% |
2,868
-128
| -4% | -$34.1K |
2018 Q2
30 quarters
|
|
155
Banco Bilbao Vizcaya Argentaria
BBVA
$138B
| $733K | 0.04% |
31,426
| – | – |
2020 Q3
21 quarters
|
|
156
Shell
SHEL
$299B
| $733K | 0.04% |
9,969
| – | – |
2022 Q2
14 quarters
|
|
157
Booking.com
BKNG
$111B
| $718K | 0.04% |
3,350
| – | – |
2019 Q1
27 quarters
|
|
158
Vanguard ESG US Stock ETF
ESGV
$13.5B
| $711K | 0.04% |
5,877
+446
| +8% | +$53.5K |
2025 Q2
2 quarters
|
|
159
UBS Group
UBS
$141B
| $704K | 0.04% |
15,199
+303
| +2% | +$12.2K |
2021 Q2
18 quarters
|
|
160
Pfizer
PFE
$168B
| $701K | 0.04% |
28,141
-759
| -3% | -$19.1K |
2018 Q3
29 quarters
|
|
161
AT&T
T
$139B
| $700K | 0.04% |
28,181
-6,536
| -19% | -$165K |
2015 Q4
40 quarters
|
|
162
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$22.1B
| $678K | 0.04% |
5,682
-694
| -11% | -$82.3K |
2022 Q4
12 quarters
|
|
163
Sana Biotechnology
SANA
$787M
| $676K | 0.04% |
166,065
-46,435
| -22% | -$208K |
2021 Q2
18 quarters
|
|
164
Altria Group
MO
$123B
| $671K | 0.04% |
11,631
-1,235
| -10% | -$74.6K |
2018 Q4
28 quarters
|
|
165
Allstate
ALL
$63.3B
| $665K | 0.04% |
3,197
+39
| +1% | +$7.98K |
2019 Q2
26 quarters
|
|
166
Regeneron Pharmaceuticals
REGN
$83.7B
| $657K | 0.04% |
851
+6
| +0.7% | +$4.08K |
2020 Q2
22 quarters
|
|
167
Intuit
INTU
$87.7B
| $654K | 0.04% |
988
-411
| -29% | -$272K |
2019 Q1
27 quarters
|
|
168
Northrop Grumman
NOC
$78.5B
| $651K | 0.04% |
1,142
-284
| -20% | -$165K |
2019 Q1
27 quarters
|
|
169
T-Mobile US
TMUS
$159B
| $646K | 0.04% |
3,182
-40
| -1% | -$8.48K |
2020 Q2
22 quarters
|
|
170
Schwab US Large- Cap ETF
SCHX
$74.8B
| $638K | 0.04% |
23,712
| – | – |
2025 Q2
2 quarters
|
|
171
Expeditors International
EXPD
$25.6B
| $630K | 0.04% |
4,226
+11
| +0.3% | +$1.5K |
2017 Q4
32 quarters
|
|
172
Cencora
COR
$61.9B
| $627K | 0.04% |
1,855
+2
| +0.1% | +$682 |
2021 Q1
19 quarters
|
|
173
Bristol-Myers Squibb
BMY
$126B
| $621K | 0.04% |
11,510
-1,027
| -8% | -$49.4K |
2018 Q3
29 quarters
|
|
174
Lyell Immunopharma
LYEL
$268M
| $614K | 0.04% |
19,958
| – | – |
2021 Q4
16 quarters
|
|
175
Constellation Energy
CEG
$91.4B
| $607K | 0.03% |
1,719
-93
| -5% | -$33.8K |
2022 Q3
13 quarters
|
|
Similar funds
Clarius Group LLC's Q4 2025 Portfolio in Review
As of Q4 2025, Clarius Group LLC held 411 positions worth $1.75B, up 3.7% from $1.69B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Clarius Group LLC's Q4 2025 filing shows 13 new, 98 increased, 159 reduced and 27 closed positions. Its largest new stake was Capital Group Global Equity ETF: 1,103,189 shares worth $34.9M. The largest sale was Microsoft, an estimated $4.12M.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, up from 48% a quarter earlier, followed by Industrials and Technology.
- Clarius Group LLC's largest Q4 2025 buy was Capital Group Global Equity ETF: 1,103,189 shares worth $34.9M.
- Clarius Group LLC added most to Vanguard Ultra-Short Bond ETF in Q4 2025, an estimated $5.25M increase.
- Clarius Group LLC's biggest Q4 2025 reduction was Microsoft, cutting an estimated $4.12M.
- Clarius Group LLC fully exited KKR & Co in Q4 2025, selling an estimated $650K.
- Clarius Group LLC's ten largest holdings make up 60% of its $1.75B portfolio in Q4 2025.
- Clarius Group LLC opened 13 new positions and closed 27 in Q4 2025.
- Clarius Group LLC's portfolio value rose 3.7% quarter-over-quarter to $1.75B.
Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.